INTRANASAL ESKETAMINE IN TREATMENT-RESISTANT DEPRESSION: WHY DO REAL-WORLD CLINICAL PRACTICE OUTCOMES SURPASS THOSE OF CLINICAL TRIALS? A NARRATIVE REVIEW
Intranasal esketamine was approved for the treatment of treatment-resistant depression on the basis of randomized clinical trials whose effects, when pooled in meta-analyses, were of modest magnitude. In contrast, observational studies conducted in routine clinical practice have reported substantial symptom reductions...